News Formal

Amgen Reports 5% Rise in Q3 Product Sales After Horizon Therapeutics Acquisition

  • 📰 SaltWire Network
  • ⏱ Reading Time:
  • 18 sec. here
  • 11 min. at publisher
  • 📊 Quality Score:
  • News: 41%
  • Publisher: 63%

Business ニュース

Amgen,Horizon Therapeutics,Acquisition

Amgen announces a 5% increase in third-quarter product sales, driven by double-digit volume growth but offset by lower prices. The company also raises its post-acquisition sales forecast and adjusted earnings outlook for 2023.

Watch on - Amgen, which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.

Wall Street analysts, on average, have forecast 2023 earnings of $18.47 per share on revenue of $28 billion, according to LSEG data. Investors will be keen to see whether Amgen, which has operations around the world, can help boost sales of Horizon's two key products, thyroid eye disease treatment Tepezza and gout drug Krystexxa.

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 45. in JP

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

London stocks rise on strong earning reports; BoE decision in focusMarket News
ソース: KitcoNewsNOW - 🏆 13. / 78 続きを読む »